These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37540787)

  • 1. Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.
    Schmeusser BN; Biermann H; Nicaise EH; Ali AA; Patil DH; Midenberg E; Helman T; Armas-Phan M; Nabavizadeh R; Joshi SS; Narayan VM; Bilen MA; Psutka SP; Ogan K; Master VA
    Oncologist; 2023 Dec; 28(12):e1219-e1229. PubMed ID: 37540787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.
    Schmeusser BN; Midenberg E; Palacios AR; Ali AA; Patil DH; Higgins M; Nabavizadeh R; Croll B; Williams M; Sheehy J; Zheng B; Narayan VM; Joshi SS; Ogan K; Psutka SP; Bilen MA; Master VA
    Clin Genitourin Cancer; 2023 Aug; 21(4):475-482.e4. PubMed ID: 37210313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
    Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
    Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma.
    Midenberg E; Higgins MI; Schmeusser BN; Patil DH; Zaldumbide J; Martini DJ; Steele S; Williams M; Nabavizadeh R; Psutka SP; Ogan K; Bilen MA; Master VA
    Urol Oncol; 2023 Jan; 41(1):50.e19-50.e26. PubMed ID: 36280529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy.
    Lee J; Suh J; Song C; You D; Jeong IG; Hong B; Hong JH; Kim CS; Ahn H
    Ann Surg Oncol; 2022 Apr; 29(4):2473-2479. PubMed ID: 34625877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum low-density lipoprotein cholesterol is an independent prognostic factor in patients with renal cell carcinoma after nephrectomy.
    Cui F; Zhou H; Lv D; Wen J; Gong Q; Rong Y; Kang Y; Jia M; Shuang W
    Lipids Health Dis; 2023 Feb; 22(1):26. PubMed ID: 36814277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
    Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
    Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative serum cystatin-C as a potential biomarker for prognosis of renal cell carcinoma.
    Guo S; Xue Y; He Q; He X; Guo K; Dong P; Yao K; Yang G; Chen D; Li Z; Li X; Qin Z; Liu Z; Cheng W; Guo C; Zhang M; Han H; Zhou F
    PLoS One; 2017; 12(6):e0178823. PubMed ID: 28586363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS; Ogan K; Master VA
    Cancer; 2022 Jun; 128(11):2073-2084. PubMed ID: 35285950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.
    Xue W; Zhang Y; Wang H; Zhang Y; Hu X
    Front Immunol; 2021; 12():778746. PubMed ID: 34917092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
    Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
    Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of p21-activated kinase 6 expression in patients with clear cell renal cell carcinoma.
    Liu W; Liu H; Liu Y; Xu L; Zhang W; Zhu Y; Xu J; Gu J
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S575-83. PubMed ID: 24715215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of prognostic nutritional index in renal cell carcinomas.
    Tang Y; Liang J; Liu Z; Zhang R; Zou Z; Wu K; Lu Y; Wei X
    Medicine (Baltimore); 2021 Mar; 100(10):e25127. PubMed ID: 33725913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of perioperative blood transfusion on oncologic outcomes in patients with nonmetastatic renal cell carcinoma treated with curative nephrectomy: A retrospective analysis of a large, single-institutional cohort.
    Seon DY; Kwak C; Kim HH; Ku JH; Kim HS
    Investig Clin Urol; 2020 Mar; 61(2):136-145. PubMed ID: 32158964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sarcopenia in treatment-related outcomes in patients with renal cell carcinoma: A systematic review and meta-analysis.
    Yuxuan L; Junchao L; Wenya L
    Medicine (Baltimore); 2022 Oct; 101(43):e31332. PubMed ID: 36316941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality Increases When Radical Nephrectomy is Delayed More Than 60 Days for T3 Renal Cell Carcinoma.
    Zhao F; Liu X; Zhang C; Zhu H; Qi N
    Technol Cancer Res Treat; 2021; 20():15330338211043963. PubMed ID: 34595976
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy.
    Chen L; Ma X; Li H; Gu L; Li X; Gao Y; Xie Y; Zhang X
    PLoS One; 2017; 12(3):e0173953. PubMed ID: 28288191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma.
    Andrade HS; Zargar H; Caputo PA; Akca O; Kara O; Ramirez D; Haber GP; Stein RJ; Kaouk JH
    Eur Urol; 2016 Jun; 69(6):1149-54. PubMed ID: 26719014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.